1. Home
  2. MOBX vs NEUP Comparison

MOBX vs NEUP Comparison

Compare MOBX & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mobix Labs Inc.

MOBX

Mobix Labs Inc.

HOLD

Current Price

$2.94

Market Cap

25.4M

Sector

N/A

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.95

Market Cap

23.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MOBX
NEUP
Founded
2020
1996
Country
United States
United States
Employees
46
8
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
25.4M
23.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MOBX
NEUP
Price
$2.94
$4.95
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
5.1M
44.8K
Earning Date
05-14-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.13
$3.65
52 Week High
$3.87
$21.31

Technical Indicators

Market Signals
Indicator
MOBX
NEUP
Relative Strength Index (RSI) 65.34 62.31
Support Level $0.46 $3.85
Resistance Level $3.87 $5.18
Average True Range (ATR) 0.42 0.22
MACD 0.02 0.04
Stochastic Oscillator 42.42 87.21

Price Performance

Historical Comparison
MOBX
NEUP

About MOBX Mobix Labs Inc.

Mobix Labs Inc designs, develops and sells components and systems for wireless and wired connectivity, radio frequency (RF), switching and electromagnetic interference (EMI) filtering technologies. Its wireless systems solutions include products for RF and millimeter wave (mmWave) communications, mmWave imaging, software defined radio and custom RF integrated circuits (ICs) targeting the defense, aerospace, commercial and industrial sectors. The majority of the company's revenue is derived from product sales to equipment manufacturers. Geographically, it generates the maximum revenue from the United States.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: